{"id":"W3032723625","doi":"10.1200/jco.2020.38.15_suppl.tps596","title":"KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC).","year":2020,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Gemcitabine; Oncology; Chemotherapy; Internal medicine; Carboplatin; Pembrolizumab; Olaparib; Induction chemotherapy; Immunotherapy; Cancer; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003139217,0.002402002,0.002621779,0.000522026,0.0005481186,0.001569163,0.001522505,0.002367899,0.01215642],"category_scores_gemma":[0.001888979,0.001002364,0.001837842,0.0005056064,0.001354281,0.001781588,0.0006375056,0.004867782,0.002373039],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001411114,"about_ca_system_score_gemma":0.002493287,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001290166,"about_ca_topic_score_gemma":0.003655052,"domain_scores_codex":[0.9992501,0.0004010811,0.00003807801,0.0001292298,0.00005702586,0.0001243358],"domain_scores_gemma":[0.9987124,0.0002279707,0.0003105529,0.00007612358,0.00008373777,0.0005892529],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9520503,0.02420079,0.000674491,0.0008103763,0.0007281148,0.00003936851,0.00005328175,0.000339379,0.004413724,0.000160716,0.00198027,0.01454921],"study_design_scores_gemma":[0.932743,0.06478447,0.0008482403,0.00002317188,0.0002548264,0.00002615676,0.00001908086,0.0002695379,0.0002367432,0.00009934318,0.0006842437,0.00001120832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9468359,0.006665431,0.001648156,0.002915382,0.001718593,0.02795907,0.005695142,0.0004639814,0.006098362],"genre_scores_gemma":[0.9400858,0.004743334,0.005229374,0.004676803,0.0007897489,0.0291355,0.004970943,0.0001173442,0.01025122],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.01215642,"threshold_uncertainty_score":0.0406673,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1116111870093552,"score_gpt":0.4469118101571758,"score_spread":0.3353006231478207,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}